Evolving therapeutic indications for N-type calcium channel blockers: From chronic pain to alcohol abuse

Future Medicinal Chemistry

Volumn 2, Issue 5, 2010, Pages 791-802

  Belardetti, Francesco ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [6,6 BIS(4 FLUOROPHENYL)HEXYL] 4 (3,4,5 TRIMETHOXYBENZYL)PIPERAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR; ACAMPROSATE; BACLOFEN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; DISULFIRAM; DOPAMINE; NALTREXONE; NMED 216; NP 078585; OMEGA CONOTOXIN MVIIA; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; ALCOHOLISM; CHRONIC PAIN; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; NEUROPATHIC PAIN; NONHUMAN; PAIN; PLACE PREFERENCE; PRIORITY JOURNAL; REVIEW; REWARD; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; CHRONIC DISEASE; HUMANS; PAIN;

EID: 77953452904     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.30     Document Type: Review

References (149)

1. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57 (4), 411-425 (2005).
2. 2+ channels: a functional patchwork. Trends Neurosci. 26 (12), 683-687 (2003).
3. Wamhoff BR, Bowles DK, Owens GK. Excitation-transcription coupling in arterial smooth muscle. Circ. Res. 98 (7), 868-878 (2006).
4. Dunlap K, Luebke JI, Turner TJ. Exocytotic Ca2+ channels in mammalian central neurons. Trends Neurosci. 18 (2), 89-98 (1995).
5. Kisilevsky AE, Zamponi GW. Presynaptic calcium channels: structure, regulators, and blockers. Handb Exp. Pharmacol. (184), 45-75 (2008).
6. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol. Rev. 83 (1), 117-161 (2003).
7. Triggle DJ. L-type calcium channels. Curr. Pharm. Des. 12 (4), 443-457 (2006).
8. Welling A, Kwan Y W, Bosse E et al. Subunit-dependent modulation of recombinant L-type calcium channels. Molecular basis for dihydropyridine tissue selectivity. Circ. Res. 73 (5), 974-980 (1993).
9. Hu H, Marban E. Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specifc gating properties. Mol. Pharmacol. 53 (5), 902-907 (1998).
10. Bell TJ, Thaler C, Castiglioni AJ, Helton TD, Lipscombe D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron. 41 (1), 127-138 (2004).
11. 2+ channels. Annu. Rev. Cell Dev. Biol. 16, 521-555 (2000).
12. v2 calcium channels. Pharmacol. Rev. 58 (4), 837-862 (2006).
13. Catterall WA, Few AP. Calcium channel regulation and presynaptic plasticity. Neuron. 59 (6), 882-901 (2008).
14. Belardetti F, Zamponi GW. Linking calcium-channel isoforms to potential therapies. Curr. Opin. Investig. Drugs. 9 (7), 707-715 (2008).
15. Mosharov EV, Larsen KE, Kanter E et al. Interplay between cytosolic dopamine, calcium, and a-synuclein causes selective death of substantia nigra neurons. Neuron. 62 (2), 218-229 (2009).
16. Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci. 32 (5), 249-256 (2009).
17. Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. (1), CD000206 (2004).
18. Anderson SM, Famous KR, Sadri-Vakili G et al. CaMKII: a biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking. Nat. Neurosci. 11 (3), 344-353 (2008).
19. Brogden RN, Markham A, Mibefradil A. review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. Drugs 54 (5), 774-793 (1997).
20. Huguenard JR. Neuronal circuitry of thalamocortical epilepsy and mechanisms of antiabsence drug action. Adv. Neurol. 79, 991-999 (1999).
21. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin. Neuropharmacol. 30 (4), 230-240 (2007).
22. Salter MW. Cellular signalling pathways of spinal pain neuroplasticity as targets for analgesic development. Curr. Top. Med. Chem. 5 (6), 557-567 (2005).
23. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32, 1-32 (2009).
24. Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2 (4), 662-670 (2005).
25. Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: Specificity, recruitment and plasticity. Brain Res. Rev. 60 (1), 214-225 (2009).
26. Hille B, Beech DJ, Bernheim L et al. Multiple G-protein-coupled pathways inhibit N-type Ca channels of neurons. Life Sci. 56 (11-12), 989-992 (1995).
27. Bovill JG. Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. Eur. J. Anaesthesiol. Suppl. 15, 9-15 (1997).
28. Zamponi GW, Snutch TP. Modulation of voltage-dependent calcium channels by G proteins. Curr. Opin. Neurobiol. 8 (3), 351-356 (1998).
29. Christie MJ, Connor M, Vaughan CW, Ingram SL, Bagley EE. Cellular actions of opioids and other analgesics: implications for synergism in pain relief. Clin. Exp. Pharmacol. Physiol. 27 (7), 520-523 (2000).
30. Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev. 60 (1), 84-89 (2009).
31. Vaughan CW, Ingram SL, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature 390 (6660), 611-614 (1997). □ First clear indication that specific metabolites of arachidonic acid mediate at least a part of the action of opioids on GABAergic neurons.
32. Han TS, Teichert RW, Olivera BM, Bulaj G. Conus venoms - a rich source of peptidebased therapeutics. Curr. Pharm. Des. 14 (24), 2462-2479 (2008).
33. Kerr LM, Filloux F, Olivera BM, Jackson H, Wamsley JK. Autoradiographic localization of calcium channels with [125I]θ-conotoxin in rat brain. Eur. J. Pharmacol. 146 (1), 181-183 (1988).
34. Westenbroek RE, Hell JW, Warner C et al. Biochemical properties and subcellular distribution of an N-type calcium channel a1 subunit. Neuron 9 (6), 1099-1115 (1992).
35. Gohil K, Bell JR, Ramachandran J, Miljanich GP. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC). Brain Res. 653 (1-2), 258-266 (1994).
36. 2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J. Neurosci. 18 (16), 6319-6330 (1998).
37. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J. Pharmacol. Exp. Ther. 269 (3), 1117-1123 (1994).
38. Neugebauer V, Vanegas H, Nebe J, Rümenapp P, Schaible HG. Effects of N- and L-type calcium channel antagonists on the responses of nociceptive spinal cord neurons to mechanical stimulation of the normal and the inflamed knee joint. J. Neurophysiol. 76 (6), 3740-3749 (1996).
39. Bowersox SS, Gadbois T, Singh T et al. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J. Pharmacol. Exp. Ther. 279 (3), 1243-1249 (1996).
40. Sluka KA. Blockade of calcium channels can prevent the onset of secondary hyperalgesia and allodynia induced by intradermal injection of capsaicin in rats. Pain 71 (2), 157-164 (1997).
41. Suh HW, Song DK, Choi SR, Huh SO, Kim YH. Differential effects of ω-conotoxin GVIA, nimodipine, calmidazolium and KN-62 injected intrathecally on the antinociception induced by β-endorphin, morphine and [D-Ala2, N-MePhe4, Gly-ol5]-enkephalin administered intracerebroventricularly in the mouse. J. Pharmacol. Exp. Ther. 282 (2), 961-966 (1997).
42. Yamamoto T, Sakashita Y. Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat. Brain Res. 794 (2), 329-332 (1998).
43. Sluka KA. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J. Pharmacol. Exp. Ther. 287 (1), 232-237 (1998).
44. 2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp. Brain Res. 147 (4), 456-463 (2002).
45. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11 (23), 3029-3040 (2004).
46. Turner JA, Sears JM, Loeser JD. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin. J. Pain 23 (2), 180-195 (2007).
47. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin. Pharmacother. 9 (9), 1575-1583 (2008).
48. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat. Rev. Drug Discov. 8 (1), 69-85 (2009).
49. 2+ channels. Neuroreport 12 (11), 2423-2427 (2001). □ Clear validation of the role of N-type channels in pain transmission using transgenic mice.
50. 2+ channel. EMBO J. 20 (10), 2349-2356 (2001). □ Clear validation of the role of N-type channels in pain transmission using transgenic mice.
51. Kim C, Jun. K, Lee T et al. Altered nociceptive response in mice deficient in the a (1B) subunit of the voltage-dependent calcium channel. Mol. Cell. Neurosci. 18 (2), 235-245 (2001). □ Clear validation of the role of N-type channels in pain transmission using transgenic mice.
52. Seko T, Kato M, Kohno H et al. Structureactivity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 11 (16), 2067-2070 (2001).
53. Teodori E, Baldi E, Dei S et al. Design, synthesis, and preliminary pharmacological evaluation of 4-aminopiperidine derivatives as N-type calcium channel blockers active on pain and neuropathic pain. J. Med. Chem. 47 (24), 6070-6081 (2004).
54. Knutsen L J S, Hobbs CJ, Earnshaw CG et al. Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 17 (3), 662-667 (2007).
55. Zamponi GW, Feng Z, Zhang L et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 19 (22), 6467-6472 (2009).
56. Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med. 9 (5), 505-517 (2008).
57. Belardetti F, Ahn S, So K, Snutch TP, Phillips AG. Block of voltage-gated calcium channels stimulates dopamine efflux in rat mesocorticolimbic system. Neuropharmacol. 56 (6-7), 984-993 (2009). □ Describes a clear link between N-type channel block and enhanced dopamine release in free-moving animals.
58. Solem, M, McMahon T, Messing RO. Protein kinase A regulates regulates inhibition of N- and P/Q-type calcium channels by ethanol in PC12 cells. J. Pharmacol. Exp. Ther. 282 (3), 1487-1495 (1997).
59. McMahon T, Andersen R, Metten P, Crabbe JC, Messing RO. Protein kinase C ε mediates up-regulation of N-type calcium channels by ethanol. Mol. Pharm. 57 (1), 53-58 (2000).
60. Morris R G M. Elements of a neurobiological theory of hippocampal function: the role of synaptic plasticity, synaptic tagging and schemas. Eur. J. Neurosci. 23 (11), 2829-2846 (2006).
61. Schoenbaum G, Roesch MR, Stalnaker TA. Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci. 29 (2), 116-124 (2006).
62. Arnsten A F T. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23 (Suppl. 1), 33-41 (2009).
63. Sherman SM. The thalamus is more than just a relay. Curr. Opin. Neurobiol. 17 (4), 417-422 (2007).
64. Newton PM, Orr CJ, Wallace MJ et al. Deletion of N-type calcium channels alters ethanol reward and reduces ethanol consumption in mice. J. Neurosci. 24 (44), 9862-9869 (2004). □ First demonstration that the N-type channel is causally linked to alcohol consumption.
65. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56 (6), 613-672 (1998).
66. Newton PM, Zeng L, Wang V et al. A blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, selfadministration, and reinstatement. J. Neurosci. 28 (45), 11712-11719 (2008).
67. Middaugh LD, Bandy AL. Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice. Psychopharmacology (Berl.). 151 (4), 321-327 (2000).
68. Anton RF, O'Malley SS, Ciraulo DA et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 (17), 2003-2017 (2006).
69. Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 36 (1), 2-10 (2001).
70. McFarland K, Ettenberg A. Naloxone blocks reinforcement but not motivation in an operant runway model of heroin-seeking behavior. Exp. Clin. Psychopharmacol. 6 (4), 353-359 (1998).
71. Lê AD, Poulos CX, Harding S et al. Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21 (3), 435-444 (1999).
72. Brown SA, Vik PW, Patterson TL, Grant I, Schuckit MA. Stress, vulnerability and adult alcohol relapse. J. Stud. Alcohol 56 (5), 538-545 (1995).
73. Newton PM, Messing RO. The N-type calcium channel is a novel target for treating alcohol use disorders. Channels (Austin). 3 (2), 77-81 (2009).
74. Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry. 28 (8), 1221-1247 (2004).
75. Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. Br. J. Pharmacol. 154 (2), 299-315 (2008).
76. Fallon JH, Koziell DA, Moore RY. Catecholamine innervation of the basal forebrain. II. Amygdala, suprarhinal cortex and entorhinal cortex. J. Comp. Neurol. 180 (3), 509-532 (1978).
77. Fallon JH, Moore RY. Catecholamine innervation of the basal forebrain. III. Olfactory bulb, anterior olfactory nuclei, olfactory tubercle and piriform cortex. J. Comp. Neurol. 180 (3), 533-544 (1978).
78. Fallon JH, Moore RY. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180 (3), 545-580 (1978).
79. Fibiger HC, Phillips AG. Mesocorticolimbic dopamine systems and reward. Ann. NY Acad. Sci. 537, 206-215 (1988).
80. Wise RA. Role of brain dopamine in food reward and reinforcement. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361 (1471), 1149-1158 (2006).
81. Schultz W. Multiple dopamine functions at different time courses. Annu. Rev. Neurosci. 30, 259-288 (2007).
82. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2 (1), 19-76 (1976).
83. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13 (5), 177-184 (1992).
84. van Os J, Kapur S. Schizophrenia. Lancet 374 (9690), 635-645 (2009).
85. Baldo BA, Kelley AE. Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology (Berl.). 191 (3), 439-459 (2007).
86. Nicola SM. The nucleus accumbens as part of a basal ganglia action selection circuit. Psychopharmacology (Berl.). 191 (3), 521-550 (2007).
87. Goto Y, Grace AA. Limbic and cortical information processing in the nucleus accumbens. Trends Neurosci. 31 (11), 552-558 (2008).
88. Everitt BJ, Belin D, Economidou D et al. Review. Neural mechanisms underlying the vulnerability to develop compulsive drugseeking habits and addiction. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 363 (1507), 3125-3135 (2008).
89. Wheeler RA, Carelli RM. Dissecting motivational circuitry to understand substance abuse. Neuropharmacology 56 (Suppl. 1), 149-159 (2009).
90. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanolinduced increase in dialysate dopamine levels in the nucleus accumbens. J. Neurosci. 18 (24), 10663-10671 (1998).
91. Phillips PE, Stamford JA. Differential recruitment of N-, P- and Q-type voltageoperated calcium channels in striatal dopamine release evoked by 'regular' and 'burst' firing. Brain Res. 884 (1-2), 139-146 (2000).
92. Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci. 30 (5), 220-227 (2007).
93. Westerink BH, Kwint HF, de Vries JB. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J. Neurosci. 16 (8), 2605-2611 (1996).
94. Cobb WS, Abercrombie ED. Distinct roles for nigral GABA and glutamate receptors in the regulation of dendritic dopamine release under normal conditions and in response to systemic haloperidol. J. Neurosci. 22 (4), 1407-1413 (2002).
95. Poncer JC, McKinney RA, Gähwiler BH, Thompson SM. Either N- or P-type calcium channels mediate GABA release at distinct hippocampal inhibitory synapses. Neuron 18 (3), 463-472 (1997).
96. Kushner MG, Abrams K, Borchardt C. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin. Psychol. Rev. 20 (2), 149-171 (2000).
97. Lê AD, Harding S, Juzytsch W, Funk D, Shaham Y. Role of a-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (Berl.). 179 (2), 366-373 (2005).
98. Marinelli PW, Funk D, Juzytsch W et al. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl.). 195 (3), 345-355 (2007).
99. Dzung Lê A, Funk D, Harding S, Juzytsch W, Fletcher PJ. The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats. Psychopharmacology (Berl.). 204 (3), 477-488 (2009).
100. Shaham Y, Stewart J. Effects of opioid and dopamine receptor antagonists on relapse induced by stress and re-exposure to heroin in rats. Psychopharmacology (Berl.). 125 (4), 385-391 (1996).
101. Lee B, Tiefenbacher S, Platt DM, Spealman RD. Pharmacological blockade of α2-adrenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 29 (4), 686-693 (2004).
102. Siggins GR, Roberto M, Nie Z. The tipsy terminal: presynaptic effects of ethanol. Pharmacol. Ther. 107 (1), 80-98 (2005).
103. Tredway TL, Guo JZ, Chiappinelli VA. N-type voltage-dependent calcium channels mediate the nicotinic enhancement of GABA release in chick brain. J. Neurophysiol. 81 (2), 447-454 (1999).
104. A receptors in the ventral tegmental area. Nat. Neurosci. 7 (2), 160-169 (2004).
105. Coull J A M, Beggs S, Boudreau D et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438 (7070), 1017-1021 (2005).
106. A receptors mediate the opposing roles of dopamine and the tegmental pedunculopontine nucleus in the motivational effects of ethanol. Eur. J. Neurosci. 29 (6), 1235-1244 (2009).
107. McBain CJ, Kauer JA. Presynaptic plasticity: targeted control of inhibitory networks. Curr. Opin. Neurobiol. 19 (3), 254-262 (2009).
108. Nugent FS, Penick EC, Kauer JA. Opioids block long-term potentiation of inhibitory synapses. Nature 446 (7139), 1086-1090 (2007).
109. Pan B, Hillard CJ, Liu Q. Endocannabinoid signaling mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine neurons. J. Neurosci. 28 (6), 1385-1397 (2008).
110. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 71, 283-306 (2009).
111. Coull J A M, Boudreau D, Bachand K et al. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 424 (6951), 938-942 (2003).
112. A receptor subtypes. Nature 451 (7176), 330-334 (2008).
113. Chen BT, Moran KA, Avshalumov MV, Rice ME. Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release. J. Neurochem. 96 (3), 645-655 (2006).
114. (B) receptor agonists on the mesolimbic dopamine system. Nat. Neurosci. 7 (2), 153-159 (2004). □ Elegant molecular dissection of the action of baclofen.
115. Roberts D C S. Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol. Behav. 86 (1-2), 18-20 (2005).
116. B receptor. CNS Drug Rev. 13 (3), 308-316 (2007).
117. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr. Drug Targets CNS Neurol. Disord. 1 (2), 141-147 (2002).
118. Ohlsen RI, Pilowsky LS. The place of partial agonism in psychiatry: recent developments. J. Psychopharmacol. (Oxford). 19 (4), 408-413 (2005).
119. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci. 8 (1), 137-142 (2006).
120. Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Exp. Opin. Investig. Drugs. 16 (6), 771-775 (2007).
121. Bergman J. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify). Exp Clin Psychopharmacol. 16 (6), 475-483 (2008).
122. Strange PG. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 29 (6), 314-321 (2008).
123. Wise RA. Forebrain substrates of reward and motivation. J. Comp. Neurol. 493 (1), 115-121 (2005).
124. Salamone JD. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav. Brain Res. 61 (2), 117-133 (1994).
125. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry. 36 (Suppl. 3), S181-190 (2003).
126. Krampe H, Stawicki S, Wagner T et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol. Clin. Exp. Res. 30 (1), 86-95 (2006).
127. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J. Subst. Abuse Treat. 36 (1), S15-S25 (2009).
128. Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu. Rev. Med. 49, 173-184 (1998).
129. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 19 (6), 517-537 (2005).
130. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J. Psychiatr. Res. 40 (5), 383-393 (2006).
131. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med. J. Aust. 176 (11), 530-534 (2002).
132. Assanangkornchai S, Srisurapanont M. The treatment of alcohol dependence. Curr. Opin. Psychiatry 20 (3), 222-227 (2007).
133. Heberlein A, Bleich S, Kornhuber J, Hillemacher T [Pharmacological treatment options for prevention of alcohol relapse]. Fortschr. Neurol. Psychiatr. 76 (7), 421-428 (2008).
134. Brady KT, Lydiard RB. The association of alcoholism and anxiety. Psychiatr. Q. 64 (2), 135-149 (1993).
135. Brady KT, Sonne SC. The role of stress in alcohol use, alcoholism treatment, and relapse. Alcohol Res. Health. 23 (4), 263-271 (1999).
136. Uhart M, Wand GS. Stress, alcohol and drug interaction: an update of human research. Addict Biol. 14 (1), 43-64 (2009).
137. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12 (2), 483-488 (1992).
138. Lisman JE, Grace AA. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46 (5), 703-713 (2005). □ Elegant and creative synthesis and rich source of new ideas.
139. A receptor subtype functions. Curr. Opin. Pharmacol. 6 (1), 18-23 (2006).
140. Sieghart W. Structure, pharmacology, and function of GABAA receptor subtypes. Adv. Pharmacol. 54, 231-263 (2006).
141. Michels G, Moss SJ. GABAA receptors: properties and trafficking. Crit. Rev. Biochem. Mol. Biol. 42 (1), 3-14 (2007).
142. A receptors: views from outside the synaptic cleft. Neuron 56 (5), 763-770 (2007).
143. A receptor shapes unique pharmacological profiles. Drug Discov. Today 14 (17-18), 866-875 (2009).
144. B receptors. Pharmacol. Ther. 110 (3), 533-543 (2006).
145. B receptor isoforms caught in action at the scene. Neuron 50 (4), 521-524 (2006).
146. B receptors. Handb. Exp. Pharmacol. (184), 373-407 (2008).
147. Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 298 (5597), 1418-1421 (2002).
148. Vargas-Perez H, Kee RT, Walton CH et al. Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats. Science 324 (5935), 1732-1734 (2009).
149. Cancedda L, Fiumelli H, Chen K, Poo M. Excitatory GABA action is essential for morphological maturation of cortical neurons in vivo. J. Neurosci. 27 (19), 5224-5235 (2007).